Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
NeuroSense Therapeutics Ltd.
(Name of Issuer)
Ordinary Shares, no par value
(Title of Class of Securities)
M74240 108
(CUSIP Number)
December 13, 2021
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. M74240 108 | 13G | Page 2 of 5 Pages |
| 1 |
NAME OF REPORTING PERSONS
E Europe Limited |
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) ☐ (b) ☒ |
| 3 |
SEC USE ONLY
|
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Gibraltar |
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 |
SOLE VOTING POWER
602,502 |
| 6 |
SHARED VOTING POWER
--- | |
| 7 |
SOLE DISPOSITIVE POWER
602,502 | |
| 8 |
SHARED DISPOSITIVE POWER
--- |
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
602,502 |
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
☐ |
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.51% (*) |
| 12 |
TYPE OF REPORTING PERSON (See instructions)
CO |
(*) Based on 10,943,534 Ordinary Shares outstanding as of December 13, 2021 (as reported on the Company’s 424(b)(4) prospectus filed with the SEC on December 13, 2021).
| CUSIP No. M74240 108 | 13G | Page 3 of 5 Pages |
| Item 1. (a) | Name of Issuer: |
NeuroSense Therapeutics Ltd.
| (b) | Address of Issuer's Principal Executive Offices: |
Medinat ha-Yehudim Street 85, Herzliya 4676670 Israel
| Item 2. (a) | Name of Person Filing: |
E Europe Limited
| (b) | Address of Principal Business Office: |
Madison Building, Midtown, Queensway, Gibraltar, GX11 1AA
| (c) | Citizenship: |
Gibraltar
| (d) | Title of Class of Securities: |
Ordinary Shares, no par value
| (e) | CUSIP Number: |
M74240 108
| Item 3. | Not applicable. |
| Item 4. | Ownership: |
| (a) | Amount beneficially owned: |
The 602,502 Ordinary Shares reported herein are held equally by Line Nominees Limited and Line Holdings Limited, as bare nominees for Line Trust Corporation Limited, a professional trustee company, in its capacity as trustee of a discretionary settlement constituted under the laws of Gibraltar, with the potential beneficiaries being certain of the remoter issue of Mr. Conrad Morris. E Europe Limited is ultimately controlled by its board of directors, and its directors have the power to vote and dispose of the Company ordinary shares held by E Europe Limited. Mr. Grahame Jackson is the sole member of E Europe Limited’s board of directors, and he may be deemed to beneficially own the securities held by E Europe Limited.
Percent of class:
See row 11 of cover page
| CUSIP No. M74240 108 | 13G | Page 4 of 5 Pages |
| (c) | Number of shares as to which such person has: |
| (i) | Sole power to vote or to direct the vote: |
See row 5 of cover page
| (ii) | Shared power to vote or to direct the vote: |
See row 6 of cover page
| (iii) | Sole power to dispose or to direct the disposition of: |
See row 7 of cover page
| (iv) | Shared power to dispose or to direct the disposition of: |
See row 8 of cover page
| Item 5. | Ownership of Five Percent or Less of a Class: |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.
| Item 6. | Ownership of More than Five Percent on Behalf of Another: |
Not applicable.
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: |
Not applicable.
| Item 8. | Identification and Classification of Members of the Group: |
Not applicable.
| Item 9. | Notice of Dissolution of Group: |
Not applicable.
| Item 10. | Certification: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
| CUSIP No. M74240 108 | 13G | Page 5 of 5 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
December 30, 2021
| E Europe Limited | ||
| /s/ Grahame Jackson | ||
| By: | Grahame Jackson | |
| Title: | Director | |